However, CB-839 showed limited efficacy in a clinical trial that enrolled patients with KEAP1 mutant lung cancer possibly because this compound targets only one of many glutamine-dependent reactions that are essential for cancer growth. Here, KEAP1 is linked to lung carcinoma.